Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07592273 Surabgene Lomparvovec Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07592273 clinical trial report covering Surabgene Lomparvovec, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600125061 Tislelizumab Non-small cell lung cancer stage IIIB Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600125061 clinical trial report covering Tislelizumab, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07598708 Cleminorexton Narcolepsy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07598708 clinical trial report covering Cleminorexton, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07598318 Pucotenlimab Advanced Bile Duct Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07598318 clinical trial report covering Pucotenlimab, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07599800 APC-101 Neuralgia, Postherpetic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07599800 clinical trial report covering APC-101, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600125457 Regorafenib Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600125457 clinical trial report covering Regorafenib, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07608224 Toripalimab HER2 Positive Muscle Invasive Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07608224 clinical trial report covering Toripalimab, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07605364 Temozolomide Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07605364 clinical trial report covering Temozolomide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07621939 Amulirafusp alfa Immunoglobulin G4-Related Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07621939 clinical trial report covering Amulirafusp alfa, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623187 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07623187 clinical trial report covering Venetoclax, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07626398 Tretinoin Lymphohistiocytosis, Hemophagocytic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07626398 clinical trial report covering Tretinoin, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07627893 Methotrexate Sodium Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07627893 clinical trial report covering Methotrexate Sodium, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.